[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shattuck Labs, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100650956","a-phase-2-study-of-sl-325-in-crohns-disease-patients-100650956",false,"NCT07753850","A Study of SL-325 in Crohn's Disease Patients","A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease","RECEPTIVE-CD1","Key Inclusion Criteria:\n\n* A diagnosis of Crohn's disease confirmed by endoscopy and histopathology ≥ 3 months prior to Screening\n* Moderately to severely active CD as defined by CDAI of ≥ 220 and ≤ 450\n* SES-CD score ≥ 6 if ileocolonic or colonic disease, or ≥ 4 if isolated ileal disease, as assessed by central review\n* Demonstrated inadequate response, loss of response, or intolerance to one or more of the following Crohn's disease treatments: corticosteroids, immunomodulators, or an approved anti-tumor necrosis factor (TNF), anti-integrin, anti-interleukin (IL)-12\u002F23, anti-interleukin (IL)-23p19, or Janus kinase inhibitor (JAK)\n\nKey Exclusion Criteria:\n\n* Diagnosis of UC, indeterminate colitis, or any other gastrointestinal condition that could undermine the diagnosis of CD\n* CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and\u002For ileal involvement\n* Presence or suspicion of any of the following CD complications: intra-abdominal or perianal abscess; symptomatic stricture or colonic stenosis not passable in ileocolonoscopy, fistula, except for perianal fistula; active toxic megacolon or fulminant colitis; short bowel syndrome\n* Surgical bowel resection within 3 months before Screening, ≥ 3 bowel resections, or previous ileo-colonic resection of \\> 2 segments\n* Diagnosis of primary sclerosing cholangitis\n* Has a stoma, ileostomy, or colostomy.\n* Has prior or current gastrointestinal dysplasia, other than a completely removed low-grade dysplastic lesion.\n* Has active tuberculosis (TB) or inadequately treated latent tuberculosis (LTBI)\n* Prior exposure to any anti-DR3 or anti-TL1A agent or agent with an anti-DR3 or anti-TL1A component","ALL","18 Years","80 Years",{"count":21,"type":22},232,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease.\n\nThe study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.",[28],"Crohn's Disease","NOT_YET_RECRUITING","2026-08-10",{"date":32,"type":33},"2026-08-12","ACTUAL",{"date":35,"type":22},"2026-10",{"date":37,"type":22},"2030-06",{"name":39,"class":40},"Shattuck Labs, Inc.","INDUSTRY",""]